drugset / Trial / NCT04410094

A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

NCT04410094

Phase 1 Completed 32 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the effects of multiple doses of strong cytochrome P450 (CYP) 3A4 inhibitor itraconazole and strong CYP3A4 inducer rifampin on the single dose pharmacokinetics (PK) of lazertinib in healthy adult participants.

Timeline

Start
2020-09-14
Primary completion
2020-12-30
Completion
2021-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule Oral
Subject Lazertinib Small molecule Oral
Subject Rifampin Small molecule Oral

Indications

No indication recorded.